Kala Pharmaceuticals (KALA) Misses Q3 EPS by 126c

Kala Pharmaceuticals (NASDAQ: KALA) reported Q3 EPS of ($3.41), $1.26 worse than the analyst estimate of ($2.15).

For earnings history and earnings-related data on Kala Pharmaceuticals (KALA) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
• Cracker Barrel (CBRL) Tops Q4 EPS by 89c, Offers Guidance